Updated response rates and survival analysis
| . | RH arm (n = 17) . | RB arm (n = 35) . |
|---|---|---|
| Updated response rates | ||
| ORR (95% CI), % | 94.1 (71.3-99.9) | 85.7 (69.7-95.2) |
| CR, n (%) | 7 (41) | 15 (43) |
| PR, n (%) | 9 (53) | 15 (43) |
| Not evaluable, n (%) | 1 (6) | 5 (14) |
| ASCT, n (%) | 9 (53) | 23 (66) |
| No ASCT, n (%) | 8 (47) | 12 (34) |
| Median duration of response (range), mo | 51.3 (8.7-67.4) | 50.8 (2.3-64.4) |
| ASCT | 37.3 (8.7-64.4) | 51.4 (6.3-64.4) |
| No ASCT | 52.5 (43.4-67.4) | 31.2 (2.3-55.3) |
| Landmark analysis | ||
| 5-y PFS ASCT vs no ASCT (95% CI), % | 50 (15-77) vs 73 (28-93) (P = .34) | 70 (43-86) vs 63% (23-86) (P = .44) |
| 5-y OS ASCT vs No ASCT (95% CI), % | 75 (31-93) vs 73 (28-93) (P = .81) | 91 (69-98) vs 60 (20-85) (P = .055) |
| Survival analysis, % (95% CI) | ||
| PFS | ||
| 2 y | 82 (53-94) | 81 (63-91) |
| 5 y | 62 (34-81) | 66 (45-80) |
| OS | ||
| 2 y | 88 (59-97) | 87 (70-95) |
| 5 y | 74 (44-89) | 80 (62-91) |
| . | RH arm (n = 17) . | RB arm (n = 35) . |
|---|---|---|
| Updated response rates | ||
| ORR (95% CI), % | 94.1 (71.3-99.9) | 85.7 (69.7-95.2) |
| CR, n (%) | 7 (41) | 15 (43) |
| PR, n (%) | 9 (53) | 15 (43) |
| Not evaluable, n (%) | 1 (6) | 5 (14) |
| ASCT, n (%) | 9 (53) | 23 (66) |
| No ASCT, n (%) | 8 (47) | 12 (34) |
| Median duration of response (range), mo | 51.3 (8.7-67.4) | 50.8 (2.3-64.4) |
| ASCT | 37.3 (8.7-64.4) | 51.4 (6.3-64.4) |
| No ASCT | 52.5 (43.4-67.4) | 31.2 (2.3-55.3) |
| Landmark analysis | ||
| 5-y PFS ASCT vs no ASCT (95% CI), % | 50 (15-77) vs 73 (28-93) (P = .34) | 70 (43-86) vs 63% (23-86) (P = .44) |
| 5-y OS ASCT vs No ASCT (95% CI), % | 75 (31-93) vs 73 (28-93) (P = .81) | 91 (69-98) vs 60 (20-85) (P = .055) |
| Survival analysis, % (95% CI) | ||
| PFS | ||
| 2 y | 82 (53-94) | 81 (63-91) |
| 5 y | 62 (34-81) | 66 (45-80) |
| OS | ||
| 2 y | 88 (59-97) | 87 (70-95) |
| 5 y | 74 (44-89) | 80 (62-91) |
The best clinical response was determined by investigators according to the Revised Response Criteria for Malignant Lymphoma.11
CI, confidence interval; PR, partial response.